Moving forward with breast cancer prevention (Q36804143)

16 August 2017

1 reference

title

Moving forward with breast cancer prevention (English)

1 reference

16 August 2017

Graham A Colditz

3

0 references

Bernard A. Rosner

series ordinal

2

object named as

Bernard Rosner

1 reference

16 August 2017

Wendy Y Chen

1

1 reference

PubMed ID

17464950

16 August 2017

language of work or name

English

0 references

publication date

1 June 2007

1 reference

16 August 2017

1 reference

16 August 2017

109

1 reference

16 August 2017

12

1 reference

16 August 2017

2387-2391

1 reference

Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies

16 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

Numbers needed to treat derived from meta-analyses--sometimes informative, usually misleading

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Serum estradiol level and risk of breast cancer during treatment with raloxifene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Validation studies for models projecting the risk of invasive and total breast cancer incidence.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Projecting absolute invasive breast cancer risk in white women with a model that includes mammographic density.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Prospective breast cancer risk prediction model for women undergoing screening mammography

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Breast cancer risk prediction with a log-incidence model: evaluation of accuracy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Risk-benefit profile for raloxifene: 4-year data From the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.22711

7 January 2021

Identifiers

DOI

10.1002/CNCR.22711

1 reference

16 August 2017

1 reference

PubMed ID

17464950